Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Open accessThe DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Abstract
Background Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC).Patients and methods Patients with advanced NSCLC received Genexol-PM 230 mg/m(2) and cisplatin 60 mg/m(2) on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m(2) was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle.Results Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively).Conclusion Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although Genexol® PM has shown some hypersensitivity reaction in the clinic, probably due to the PEG, this is not nearly as much of a concern as for Taxol® which contains Cremophor EL [301].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [301]
In the citing paper
“The overall response rate was 37.7% and the median survival period was 21.7 months, which indicated significant improvements compared to previous clinical trials conducted with Taxol® 175–200 mg/m2 and cisplatin 75–80 mg/m2 [301].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [301]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Self-citationIn vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Self-citation
Cited by
Items 101–200 of 391
Wang, Y., Yang, T., Wang, X., Dai, W., Wang, J., Zhang, X., Li, Z., & Zhang, Q. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.027 · Cited by 73
Polymeric Micelles for Neoadjuvant Cancer Therapy and Tumor-Primed Optical Imaging
Cho, H., & Kwon, G. S. (2011) · ACS Nano · doi:10.1021/nn202676u · Cited by 73
Yang, J., Wang, X., Wang, B., Park, K., Wooley, K. L., & Zhang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114525 · Cited by 72
Self-citationHydroxyethyl starch based smart nanomedicine
Wang, H., Hu, H., Yang, H., & Li, Z. (2021) · RSC Advances · doi:10.1039/d0ra09663f · Cited by 70
Nano-Oncology: Clinical Application for Cancer Therapy and Future Perspectives
Riggio, C., Pagni, E., Raffa, V., & Cuschieri, A. (2011) · Journal of Nanomaterials · doi:10.1155/2011/164506 · Cited by 69
Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems
Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 68
Daman, Z., Ostad, S. N., Amini, M., & Gilani, K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.04.021 · Cited by 67
Miguel, R. D. A., Hirata, A. S., Jimenez, P. C., Lopes, L. B., & Costa-Lotufo, L. V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081722 · Cited by 66
Polymeric nanomedicines based on poly(lactide) and poly(lactide-co-glycolide)
Tong, R., Gabrielson, N. P., Fan, T. M., & Cheng, J. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2013.01.001 · Cited by 67
Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
Austria, E. S., Jr., Bilek, M., Varamini, P., & Akhavan, B. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102552 · Cited by 67
Clinical Translation of Self‐Assembled Cancer Nanomedicines
Mi, P., Miyata, K., Kataoka, K., & Cabral, H. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000159 · Cited by 65
Dalela, M., Shrivastav, T. G., Kharbanda, S. M., & Singh, H. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b07764 · Cited by 64
Lung Cancer Nanomedicine: Potentials and Pitfalls
Bölükbas, D. A., & Meiners, S. (2015) · Nanomedicine · doi:10.2217/nnm.15.155 · Cited by 64
Sabir, F., Qindeel, M., Zeeshan, M., Ain, Q. U., Rahdar, A., Barani, M., González, E., & Aboudzadeh, M. A. (2021) · Processes · doi:10.3390/pr9040621 · Cited by 63
Multi-drug delivery to tumor cells via micellar nanocarriers
Katragadda, U., Teng, Q., Rayaprolu, B. M., Chandran, T., & Tan, C. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.033 · Cited by 63
Cunningham, A. J., Robinson, M., Banquy, X., Chain, J. L., & Zhu, X. X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01091 · Cited by 64
Colloidal Drug Delivery Systems – Recent Advances With Polymeric Micelles
Mondon, K., Gurny, R., & Möller, M. (2008) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2008.832 · Cited by 64
Cui, F., Li, R., Liu, Q., Wu, P.-Y., Hu, W., Yue, G., Ding, H., Li-xia, Y., Qian, X.-P., & Liu, B.-R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.002 · Cited by 62
Polymeric nano-micelles: Versatile Platform for Targeted Delivery in Cancer
Mohamed, S. E.-S. H., Parayath, N. N., Taurin, S., & Greish, K. F. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.69 · Cited by 61
Chu, B., Zhang, L., Qu, Y., Chen, X., Peng, J., Huang, Y., & Qian, Z. (2016) · Scientific Reports · doi:10.1038/srep34069 · Cited by 55
Nanoparticle Delivery Strategies to Target Doxorubicin to Tumor Cells and Reduce Side Effects
Wang, Y., Wei, X., Zhang, C., Zhang, F., & Liang, W. P. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.24 · Cited by 59
Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy
Talelli, M., Rijcken, C. J. F., Hennink, W. E., & Lammers, T. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.003 · Cited by 58
The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
Holder, J. E., Ferguson, C., Oliveira, E., Lodeiro, C., Trim, C. M., Byrne, L. J., Bértolo, E., & Wilson, C. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154318 · Cited by 56
Transferrin receptor targeted PLA-TPGS micelles improved efficacy and safety in docetaxel delivery
Singh, R. P., Sharma, G., Sonali, Agrawal, P., Pandey, B. L., Koch, B., & Muthu, M. S. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.11.081 · Cited by 56
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01692-4 · Cited by 56
The potential of polymeric micelles in the context of glioblastoma therapy
Morshed, R. A., Cheng, Y., Auffinger, B., Wegscheid, M. L., & Lesniak, M. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00157 · Cited by 56
Hoang, B., Ekdawi, S. N., Reilly, R. M., & Allen, C. J. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400315p · Cited by 54
Li, L., He, X., Su, H. H., Zhou, D., Song, H., Wang, L., & Jiang, X. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75186 · Cited by 54
Qu, C., Li, J., Zhou, Y., Yang, S.-D., Chen, W., Li, F., You, B., Liu, Y., & Zhang, X. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0195-8 · Cited by 53
Self-assembling polymer systems for advanced treatment of cancer and inflammation
Palao‐Suay, R., Gómez‐Mascaraque, L. G., Aguilar, M. R., Vázquez‐Lasa, B., & Román, J. S. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.07.005 · Cited by 54
Current taxane formulations and emerging cabazitaxel delivery systems
Sun, B., Straubinger, R. M., & Lovell, J. F. (2018) · Nano Research · doi:10.1007/s12274-018-2171-0 · Cited by 53
Polymeric micelles: a ray of hope among new drug delivery systems
Kapse, A., Anup, N., Patel, V., Saraogi, G. K., Mishra, D. K., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814487-9.00006-5 · Cited by 51
Xu, L. L., Xu, S., Wang, H., Zhang, J., Chen, Z., Pan, L., Wang, J., Wei, X., Xie, H., Zhou, L., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14496 · Cited by 50
Ionizable polymeric micelles (IPMs) for efficient siRNA delivery
Zhou, Z., Yu, F., Jiang, M., Yao, Z., Wang, J., Pan, F., Feng, R., Zhao, C., Ma, Y., Zhou, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55721-w · Cited by 49
Systemic Administration of Polymer‐Coated Nano‐Graphene to Deliver Drugs to Glioblastoma
Moore, T. L., Podilakrishna, R., Rao, A. M., & Alexis, F. (2014) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201300379 · Cited by 49
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Yang, D., Yu, L., & Van, S. (2010) · Cancers · doi:10.3390/cancers3010017 · Cited by 49
Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer
Sarma, K., Akhter, M. H., Ahmad, I. S., Afzal, O., Altamimi, A. S. A., Alossaimi, M. A., Jaremko, M., Emwas, A.-H. M., & Gautam, P. (2024) · Molecules · doi:10.3390/molecules29051076 · Cited by 48
Nanotechnologies for Noninvasive Measurement of Drug Release
Moore, T. L., Chen, H., Morrison, R. A., Wang, F., Anker, J. N., & Alexis, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400419k · Cited by 48
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy
García-Fernández, C., Fornaguera, C., & Borrós, S. (2020) · Cancers · doi:10.3390/cancers12061609 · Cited by 48
The Nanosystems Involved in Treating Lung Cancer
Crintea, A., Duţu, A., Samaşcă, G., Florian, I. A., Lupan, I., & Craciun, A. M. (2021) · Life · doi:10.3390/life11070682 · Cited by 48
Li, Y., Jin, M., Shao, S., Huang, W., Yang, F., Chen, W., Zhang, S., Xia, G., & Gao, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-329 · Cited by 48
Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
Hu, X., Xia, F., Lee, J., Li, F., Lu, X., Zhuo, X., Nie, G., & Ling, D. (2021) · Advanced Science · doi:10.1002/advs.202002545 · Cited by 47
Taxanes prodrug-based nanomedicines for cancer therapy
Sun, L., Zhao, P., Chen, M., Leng, J., Luan, Y., Du, B., Yang, J. M., Yang, Y., & Rong, R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.004 · Cited by 47
Rapoport, N. Y., Gupta, R., Kim, Y.-S., & O’Neill, B. E. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.010 · Cited by 47
The advancements and prospective developments in anti-tumor targeted therapy
Leng, G., Duan, B., Liu, J., Song, L., Zhao, W., Wang, S., Hou, G., & Qu, J. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101024 · Cited by 46
Near-Infrared Light-Triggered Polymeric Nanomicelles for Cancer Therapy and Imaging
Li, L., Pang, X., & Liu, G. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00648 · Cited by 45
Palma, G., Conte, C., Barbieri, A., Bimonte, S., Luciano, A., Rea, D., Ungaro, F., Tirino, P., Quaglia, F., & Arra, C. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.058 · Cited by 43
Polymer Nanoassemblies for Cancer Treatment and Imaging
Lee, H. J., Ponta, A., & Bae, Y. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.70 · Cited by 43
Huang, W.-C., Burnouf, P., Su, Y.-C., Chen, B., Chuang, K., Lee, C., Wei, P., Cheng, T., & Roffler, S. R. (2016) · ACS Nano · doi:10.1021/acsnano.5b05661 · Cited by 42
Tam, Y. T., Shin, D. H., Chen, K. E., & Kwon, G. S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.017 · Cited by 41
Keam, B., Lee, K., Lee, S., Kim, J.-S., Kim, J. H., Wu, H.-G., Eom, K., Kim, S., Ahn, S., Chung, E., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0070 · Cited by 40
Self-citationvan Eerden, R. A. G., Mathijssen, R. H. J., & Koolen, S. L. W. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272529 · Cited by 40
Wang, Y., Wu, K.-C., Zhao, B., Zhao, X. S., Wang, X., Chen, S., Nie, S., Pan, W., Zhang, X., & Zhang, Q. (2011) · BioMed Research International · doi:10.1155/2011/854872 · Cited by 40
Production of paclitaxel-loaded PEG-b-PLA micelles using PEG for drug loading and freeze-drying
Rasoulianboroujeni, M., Repp, L., Lee, H. J., & Kwon, G. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.032 · Cited by 39
Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT
Zhang, L., Yang, J., Huang, J., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · Chem · doi:10.1016/j.chempr.2023.12.019 · Cited by 39
Kim, H. S., Lee, J. Y., Lim, S. H., Sun, J., Lee, S., Ahn, J. S., Park, K., Moon, S. H., & Ahn, M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000692 · Cited by 39
Self-citationRichter, A., Olbrich, C., Krause, M., & Kissel, T. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.032 · Cited by 38
“The key advantage of this formulation is a significantly ncreased maximum tolerated dose (MTD) in humans compared o Taxol® and the absence of carrier-related side effects (Kim et al., 001; Kim et al., 2004; Kim et al., 2007; Lee et al., 2008).”
BackgroundDrug delivery and nanodetection in lung cancer
Badrzadeh, F., Rahmati‐Yamchi, M., Badrzadeh, K., Valizadeh, A., Zarghami, N., Farkhani, S. M., & Akbarzadeh, A. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.975237 · Cited by 38
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)
Ashique, S., Garg, A., Mishra, N., Raina, N., Ming, L. C., Tuli, H. S., Behl, T., Rani, R., & Gupta, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02522-5 · Cited by 37
Improving chemoradiotherapy with nanoparticle therapeutics
The University of North Carolina at Chapel Hill University Libraries (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.08.04 · Cited by 37
Wang, A., Cummings, N. D., Sethi, M., Wang, E., Sukumar, R., Moore, D. T., & Werner, M. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e13546 · Cited by 37
Chowdhury, S., Yusof, F., Salim, W. W. A. W., Sulaiman, N., & Faruck, M. O. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.09.013 · Cited by 36
Serras, A. S., Faustino, C. M. C., & Pinheiro, L. M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081047 · Cited by 35
The emerging role of cancer nanotechnology in the panorama of sarcoma
Mercatali, L., Vanni, S., Miserocchi, G., Liverani, C., Spadazzi, C., Cocchi, C., Calabrese, C., Gurrieri, L., Fausti, V., Riva, N., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.953555 · Cited by 35
A simple method to improve the stability of docetaxel micelles
Zhang, L., Tan, L., Chen, L., Chen, X., Long, C., Peng, J., & Qian, Z. (2016) · Scientific Reports · doi:10.1038/srep36957 · Cited by 35
Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease
Vanderburgh, J. P., Kwakwa, K. A., Werfel, T. A., Merkel, A. R., Gupta, M. K., Johnson, R. W., Guelcher, S. A., Duvall, C. L., & Rhoades, J. A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.038 · Cited by 35
Phytonanomedicine: a novel avenue to treat recurrent cancer by targeting cancer stem cells
Mohapatra, P., Singh, P., & Sahoo, S. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.003 · Cited by 34
Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus
Majumder, J., & Minko, T. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000203 · Cited by 34
A spotlight on alkaloid nanoformulations for the treatment of lung cancer
Sindhoor, S. M., Naveen, N. R., Rao, G. K., Gopan, G., Chopra, H., Park, M. N., Alshahrani, M. M., Jose, J., Emran, T. B., & Kim, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.994155 · Cited by 34
Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer
Kim, J. Y., Do, Y. R., SONG, H. S., Cho, Y. Y., Ryoo, H. M., Bae, S. H., Kim, J. G., Chae, Y. S., Kang, B. W., Baek, J. H., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11471 · Cited by 34
Self-citationLee, S., Kim, Y., Kim, Y. T., & Kang, S. B. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e26 · Cited by 33
Polymer Nanoparticulate Drug Delivery and Combination Cancer Therapy
Cao, P., & Bae, Y. (2012) · Future Oncology · doi:10.2217/fon.12.139 · Cited by 33
Du, N., Guo, W., Yu, Q., Guan, S., Guo, L., Shen, T., Tang, H., & Gan, Z. (2016) · Polymer Chemistry · doi:10.1039/c6py01113f · Cited by 32
Zhang, L., Liu, Z., Kong, C., Liu, C., Yang, K., Chen, H., Huang, J., & Qian, F. (2018) · Small · doi:10.1002/smll.201802112 · Cited by 32
Current Update on the Role of Enhanced Permeability and Retention Effect in Cancer Nanomedicine
Jasim, A. A., Abdelghany, S., & Greish, K. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809717-5.00002-6 · Cited by 33
Shi, M., Sun, J., Zhou, J., Yu, H., Yu, S., Xia, G., Wang, L., Teng, Y., Liu, G., Yu, C., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0506-4 · Cited by 32
Chung, H., Lee, H., Han, H., An, H., Lim, K. S., Lee, Y., Cho, J., Yoon, S. H., Jang, I., & Yu, K. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s80066 · Cited by 31
Gholap, A. D., Pardeshi, S. R., Giram, P. S., Nangare, S., Sodha, S., Kapare, H. S., More, M. P., Sonar, Y. A., Shukla, R., Naik, J., et al. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00646-6 · Cited by 30
Nanomedicine in Chemoradiation
Miller, S., & Wang, A. Z. (2013) · Therapeutic Delivery · doi:10.4155/tde.12.147 · Cited by 30
Khursheed, R., Paudel, K. R., Gulati, M., Vishwas, S., Jha, N. K., Hansbro, P. M., Oliver, B. G. G., Dua, K., & Singh, S. K. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0451 · Cited by 29
Polymeric Micelles for Drug Delivery
Wu, W., & Jiang, X. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch3 · Cited by 28
Nanomedicine Technologies for Diagnosis and Treatment of Breast Cancer
Kitsios, K., Sharifi, S., & Mahmoudi, M. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00044 · Cited by 28
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
Wileński, S., Koper, A., Śledzińska, P., Bebyn, M. G., & Koper, K. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231208978 · Cited by 28
Hirunpanich, V., & Sato, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.06.011 · Cited by 28
Wang, K., Yuan, A., Yu, J., Wu, J., & Hu, Y. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.007 · Cited by 28
Reducible Micelleplexes are Stable Systems for Anti-miRNA Delivery in Cerebrospinal Fluid
Zhang, Y., Buhrman, J. S., Liu, Y., Rayahin, J., & Gemeinhart, R. A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00933 · Cited by 28
Nano-Aggregates: Emerging Delivery Tools for Tumor Therapy
Sharma, V. K., Jain, A., & Soni, V. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013007706 · Cited by 27
PEGylated Erlotinib HCl Injectable Nanoformulation for Improved Bioavailability
Bhargave, H., Nijhawan, H. P., & Yadav, K. S. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02560-5 · Cited by 27
Polymer Micelles for Drug Delivery
Kim, S., & Park, K. (2010) · CRC Press eBooks · doi:10.1201/9781420087734-c19 · Cited by 27
Self-citationWang, Y., Xiao, S., Yu, W., Han, B. R., & Guo, G. F. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01766-3 · Cited by 26
Srinivasarao, D. A., Shah, S., Famta, P., Vambhurkar, G. B., Jain, N., Pindiprolu, S. K. S. S., Sharma, A., Kumar, R., Padhy, H. P., Kumari, M., et al. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01673-z · Cited by 26
Shin, B. S., Kim, H. J., Hong, S. H., Lee, J. B., Hwang, S. W., Lee, M. H., & Yoo, S. D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0849-9 · Cited by 26
Self-citationLee, S. Y., Park, H. S., Lee, K. Y., Kim, H. J., Jeon, Y. J., Jang, T. W., Lee, K. H., Kim, Y. C., Kim, K. S., Oh, I., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.11.005 · Cited by 26
Self-citationPharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
Hwang, S. R., Chakraborty, K., An, J. M., Mondal, J., Yoon, H. Y., & Lee, Y.-K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111875 · Cited by 25
Sun, X. Y., Zhao, R., Zhao, E., Wang, Q., Lian, W., & Xiong, J. P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113655 · Cited by 24
Synthesis, Characterization, and Self-Assembly of Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate)
Bailly, N., Pound-Lana, G., & Klumperman, B. (2012) · Australian Journal of Chemistry · doi:10.1071/ch12185 · Cited by 24
Lü, J., Gu, A., Wang, W., Huang, A., Han, B., & Zhong, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121961 · Cited by 24
Bioabsorbable engineered nanobiomaterials for antibacterial therapy
Yadav, R., & Kandasubramanian, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-41532-3.00003-8 · Cited by 24
Nanoparticulate Strategies for Effective Delivery of Poorly Soluble Therapeutics
Gokce, E. H., Özyazıcı, M., & Souto, E. B. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.4 · Cited by 24
Basingab, F. S., Alshahrani, O. A., AlAnsari, I., Almarghalani, N. A., Alshelali, N. H., Alsaiary, A. H., Alharbi, N. M., & Zaher, K. A. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s501448 · Cited by 23
Metadata
- Authors
- Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S.
- Affiliations
- Seoul National University (KR)
- Asan Medical Center (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Korea University Anam Hospital (KR)
- Samsung Medical Center (KR)
- Samyang Holdings (South Korea) (KR)
- Corresponding author
- Heo, D.S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 18
- Issue
- 12
- Pages
- 2009-2014
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2155680971
- Cited by
- 356
- References
- 27
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 19 · 2023: 13 · 2022: 24 · 2021: 12 · 2020: 22 · 2019: 15 · 2018: 19 · 2017: 18 · 2016: 30 · 2015: 24 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4385 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- paclitaxel, polymeric micelles, cisplatin, non-small cell lung cancer, combination chemotherapy, first-line therapy, dose escalation, peripheral sensory neuropathy, neutropenia, hypersensitivity, anticancer activity
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Micelles, Middle Aged, Polymers, Treatment Outcome, Paclitaxel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.